First human trial tests promising new cancer drug combo

NCT ID NCT04649385

Summary

This is an early-stage study to test the safety and find the right dose of a new experimental drug called BGB-15025. It is being tested alone and in combination with an existing immunotherapy drug (tislelizumab) in 157 patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to see how much of the drug the body can handle and to check for any serious side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, 05505, South Korea

  • Ashford Cancer Centre Research Northeast

    Windsor Gardens, South Australia, SA 5087, Australia

  • Auckland City Hospital

    Auckland, 1023, New Zealand

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150000, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Icahn School of Medicine At Mount Sinai

    New York, New York, 10029-6504, United States

  • Linear Clinical Research

    Nedlands, Western Australia, WA 6009, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, VIC 3000, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, NSW 2031, Australia

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • The Catholic University of Korea, Seoul St Marys Hospital

    SeochoGu, Seoul Teugbyeolsi, 06591, South Korea

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Ut Health San Antonio Mays Cancer Center

    San Antonio, Texas, 78229-4427, United States

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.